Viking Therapeutics Inc - Asset Resilience Ratio
Viking Therapeutics Inc (VKTX) has an Asset Resilience Ratio of 75.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VKTX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Viking Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VKTX asset base.
Liquid Assets Composition Over Time
This chart breaks down Viking Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read VKTX total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $539.93 Million | 75.44% |
| Total Liquid Assets | $539.93 Million | 75.44% |
Asset Resilience Insights
- Very High Liquidity: Viking Therapeutics Inc maintains exceptional liquid asset reserves at 75.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Viking Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Viking Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Viking Therapeutics Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Viking Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.44% | $539.93 Million | $715.73 Million | -21.00pp |
| 2024-12-31 | 96.43% | $875.94 Million | $908.32 Million | +13.24pp |
| 2023-12-31 | 83.19% | $306.56 Million | $368.49 Million | +12.67pp |
| 2022-12-31 | 70.52% | $118.85 Million | $168.53 Million | -12.90pp |
| 2021-12-31 | 83.42% | $175.73 Million | $210.66 Million | -2.07pp |
| 2020-12-31 | 85.48% | $219.27 Million | $256.50 Million | -8.54pp |
| 2019-12-31 | 94.02% | $267.26 Million | $284.26 Million | +2.48pp |
| 2018-12-31 | 91.54% | $276.74 Million | $302.31 Million | +39.16pp |
| 2017-12-31 | 52.38% | $11.59 Million | $22.12 Million | -16.93pp |
| 2016-12-31 | 69.31% | $10.08 Million | $14.54 Million | -17.06pp |
| 2015-12-31 | 86.37% | $13.34 Million | $15.44 Million | -- |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more